Lung adenocarcinomas, which account for approximately 50% of NSCLC, are molecularly subclassified and subjected to different therapeutic strategies according to the presence of distinct alterations in genes such as EGFR, ALK, and KRAS [3]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.